Approval · Notice of Compliance 13547 · 2012
TRAJENTA: Notice of Compliance 13547
Issued August 3, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13547
- Date
- August 3, 2012
- Company
- Boehringer Ingelheim (Canada) Ltd.Burlington, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to the Product Monograph regarding use in severe renal insufficiency and data from final study reports
- Therapeutic class
- Oral Antihyperglycemic Agent: DPP-4 Inhibitor; Incretin Enhancer
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TRAJENTA | Not yet assigned | — |
Medicinal ingredients
- LINAGLIPTIN 5 MG per TAB